Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services, announces the acquisition of VRL Laboratories (“VRL”), one of the leading laboratories in pre-transplant testing for the eligibility determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) in the US.
Founded in 2010, VRL has become a reference laboratory solely focused on donor eligibility testing and microbiology testing for the transplant and medical communities. The company offers a broad menu of infectious disease screening assays to support the FDA’s 21 CFR 12711 donor eligibility determination testing requirements, specifically for eye, tissue, organ, stem cell and cord blood, as well as reproductive tissues. VRL employs a total of 60 staff across its main facility in Denver CO, and its satellite laboratories in Boston, MA, Dallas, TX, and Atlanta, GA.
The acquisition of VRL reinforces Eurofins’ footprint in specialty clinical testing services and consolidates the Group’s leadership in the transplantation testing market. Furthermore, VRL’s microbiology testing services expands Eurofins’ testing portfolio and increases client penetration in the transplantation testing market. In return, VRL will have access to the Group’s clients and competencies, as well as its laboratory network infrastructure, which should support its further development.
Comment from Dr. Gilles Martin, Eurofins CEO: “The acquisition of VRL is another demonstration of our strategy of expanding and strengthening our network of competence centers. In combination with ViraCor and Diatherix, VRL reinforces the Group’s footprint in the testing market for transplantation and infectious diseases.”
Next Finance , September 2016